Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Infect Dis ; 40(10): 1395-403, 2005 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-15844060

RESUMEN

BACKGROUND: Current treatments for cutaneous leishmaniasis are limited by their toxicity, high cost, and discomfort and the emergence of drug resistance. New approaches, including combination therapies, are urgently needed. We performed a double-blind, randomized trial of therapy with parenteral antimony plus topical imiquimod, an innate immune-response modulator, versus therapy with antimony alone, in subjects with cutaneous leishmaniasis for whom an initial course of antimony therapy had failed. METHODS: Forty subjects with clinical resistance to antimony were recruited in Lima, Peru, between February 2001 and December 2002. All subjects received meglumine antimoniate (20 mg/kg/day im or iv) and were randomized to receive either topical imiquimod 5% cream (Aldara; 3M Pharmaceuticals) or vehicle control every other day for 20 days. Lesions and adverse events were evaluated during treatment and at 1, 2, 3, 6, and 12 months after the treatment period. RESULTS: The mean number of lesions was 1.2 per person; 71% of the lesions were facial and 76% were ulcerative. There were no major differences between the groups, and all but 2 subjects completed therapy. Mild adverse events were reported by 73% of the subjects, but only erythema occurred more commonly in the imiquimod group (P < or = .02). Lesions resolved more rapidly in the imiquimod group: 50% of the imiquimod group achieved cure at 1 month after the treatment period versus 15% of the vehicle cream group (P < or = .02); 61% of the imiquimod group at 2 months versus 25% of the vehicle cream group (P < or = .03); and 72% of the imiquimod group at 3 months versus 35% of the vehicle cream group (P < or = .02). Residual scarring in the imiquimod group was less prominent than in the vehicle cream group. CONCLUSIONS: Combined antimony plus imiquimod treatment was well tolerated, accelerated healing of lesions, and improved scar quality. This therapy may have particular advantages for subjects with facial lesions.


Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Aminoquinolinas/administración & dosificación , Aminoquinolinas/uso terapéutico , Antiprotozoarios/administración & dosificación , Leishmaniasis Cutánea/tratamiento farmacológico , Meglumina/administración & dosificación , Meglumina/uso terapéutico , Compuestos Organometálicos/administración & dosificación , Compuestos Organometálicos/uso terapéutico , Adyuvantes Inmunológicos/efectos adversos , Adyuvantes Inmunológicos/uso terapéutico , Administración Tópica , Adolescente , Adulto , Anciano , Aminoquinolinas/efectos adversos , Antiprotozoarios/efectos adversos , Antiprotozoarios/uso terapéutico , Niño , Preescolar , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Imiquimod , Lactante , Inyecciones Intravenosas , Masculino , Meglumina/efectos adversos , Antimoniato de Meglumina , Persona de Mediana Edad , Compuestos Organometálicos/efectos adversos , Perú
2.
La Paz; s.e.; 1984. 124 p.
Monografía en Español | LIBOCS, LIBOSP | ID: biblio-1312552

RESUMEN

Contenido:1.Leyes de las combinaciones quimicas 2.La materia gaseosa 3.Balance de materia.-Ecuaciones quimicas.-Estequiometria 4.Disoluciones 5.Equilibrio quimico 6.Equilibrio ionico-Acidos y bases 7.Termodinamica 8.Electroquimica.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA